

Ref: FOI/2023/9017

Date Received: 30th June 2023

Response Due: 28th July 2023

Date: 13th July 2023

Dear Sir/Madam

You asked:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

We have treated a total of 71 patients at the Trust, we also refer to Salford, MRI and Christie.

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- **Belantamab Mafodotin [Blenrep] – Zero**
- **Bortezomib [Velcade] monotherapy or with dexamethasone - <5**
- **Bortezomib, thalidomide and dexamethasone [VTD] - Zero**
- **Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) - <5**
- **Carfilzomib [Kyprolis] and dexamethasone - Zero**
- **Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone - Zero**
- **Daratumumab [Darzalex] monotherapy - 6**
- **Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) - 17**

- **Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) - 14**
- **Elranatamab - Zero**
- **Idecabtagene vicleucel [Abecma] - Zero**
- **Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) - Zero**
- **Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) - 12**
- **Lenalidomide [Revlmid] monotherapy - 5**
- **Lenalidomide [Revlmid] and dexamethasone - 11**
- **Pomalidomide [Imnovid] and dexamethasone - <5**
- **Selinexor and dexamethasone - Zero**
- **Talquetamab - Zero**
- **Teclistamab [Tecvayli] - Zero**
- **Any other systemic anti-cancer therapy - Zero**

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink that reads "Masterman". The signature is written in a cursive style with a long horizontal line extending from the end of the name.

Gary Masterman
Deputy Chief Pharmacist (Governance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111